Keyword Analysis & Research: racarbrio
Keyword Research: People who searched racarbrio also searched
Search Results related to racarbrio on Search Engine
Dosing and Administration for RECARBRIO™ (imipenem ...
RECARBRIO is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella ...
DA: 73 PA: 41 MOZ Rank: 17
HIGHLIGHTS OF PRESCRIBING INFORMATION See Full …
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RECARBRIO safely and effectively. See full prescribing
DA: 20 PA: 64 MOZ Rank: 68
Recarbrio | European Medicines Agency
May 18, 2021 · Recarbrio is an antibiotic for treating adults with the following infections: lung infections caught in hospital (hospital-acquired pneumonia), including ventilator-associated pneumonia (pneumonia caught while on a ventilator, which is a machine that helps a patient to breathe);
DA: 73 PA: 88 MOZ Rank: 63
Recarbrio (imipenem, cilastatin, and relebactam) FDA ...
Jun 09, 2020 · Recarbrio FDA Approval History. Last updated by Judith Stewart, BPharm on June 9, 2020.. FDA Approved: Yes (First approved July 16, 2019) Brand name: Recarbrio Generic name: imipenem, cilastatin, and relebactam Dosage form: for Injection Company: Merck Treatment for: Urinary Tract Infection, Intraabdominal Infection, Nosocomial Pneumonia Recarbrio (imipenem, cilastatin, …
DA: 14 PA: 54 MOZ Rank: 71
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
The severity and location of infection, as well as clinical response should guide the duration of therapy. The recommended duration of treatment with RECARBRIO is 4 days to 14 days.
DA: 92 PA: 60 MOZ Rank: 20
Recarbrio (imipenem/cilastatin/relebactam) dosing ...
Contraindications. History of severe hypersensitivity to imipenem, cilastatin, or relebactam, or any other component. Cautions. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions reported in patients receiving therapy with beta-lactams; carefully assess allergy history for previous hypersensitivity to carbapenems, penicillins, cephalosporins, other beta-lactams, and other ...
DA: 6 PA: 91 MOZ Rank: 2
Recarbrio 500 mg/500 mg/250 mg powder for solution for ...
Apr 09, 2021 · Recarbrio 500 mg/500 mg/250 mg powder for solution for infusion - Summary of Product Characteristics (SmPC) by Merck Sharp & Dohme (UK) Limited
DA: 91 PA: 30 MOZ Rank: 70
Merck's Antibiotic Recarbrio Gets FDA Nod for New ...
Jun 08, 2020 · Merck & Co., Inc. MRK announced that the FDA has approved the supplemental new drug application (sNDA) for its new antibacterial injection Recarbrio for …
DA: 27 PA: 9 MOZ Rank: 40
What kind of infections can Recarbrio be used for?
Recarbrio is an antibiotic for treating adults with the following infections: lung infections caught in hospital (hospital-acquired pneumonia), including ventilator-associated pneumonia (pneumonia caught while on a ventilator, which is a machine that helps a patient to breathe);
DA: 47 PA: 72 MOZ Rank: 95
Is there evidence that Recarbrio is effective against Gram negative bacteria?
There were too few patients in the main study of infections caused by Gram-negative bacteria to show conclusively that Recarbrio is effective against bacteria that have become resistant to imipenem. However, studies on how the medicine works in the body provided more evidence of its effectiveness.
DA: 80 PA: 91 MOZ Rank: 65
What are the results of the Recarbrio study?
In a main study in 47 adults with infections caused by Gram-negative bacteria, 71% of patients treated with Recarbrio had a favourable outcome (based on their symptoms and test results) compared with 70% of patients treated with another combination (colistin, imipenem and cilastatin).
DA: 68 PA: 26 MOZ Rank: 56
Why was Recarbrio approved for cIAI and Cuti?
Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO.
DA: 7 PA: 94 MOZ Rank: 71